EDGAR·FLOW

Rezolute, Inc. — Form 8-K

Filed November 13, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 78/100
What the filing says
Rezolute announced that its Phase 3 upLIFT study of ersodetug achieved its primary efficacy endpoint on November 5, 2026. Of 16 enrolled participants, 13 met the responder criterion (≥50% reduction in glucose infusion rate from baseline), exceeding the statistical threshold of 9 responders (56%) required for significance; 12 of these also achieved complete IV glucose discontinuation. Topline results with full statistical analysis are expected by mid-December 2026, with FDA pre-BLA meetings planned for Q1 2027 for both tumor HI and congenital HI indications.
Why this rating

Late-stage biotech with single asset; positive Phase 3 endpoint directly de-risks regulatory path and near-term value inflection. Significant relative to ~$259M market cap.

Tradability signal
NO TRADE

No trade: positive news with only -0.6% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.09% over 4 hrs, n=474). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$4.27 ▼ 5.11%
at our read · unknown
$4.50
+10 min · unknown
$4.22 ▼ 6.11%
+30 min · unknown
$3.83 ▼ 14.89%
+1 hr · unknown
$3.73 ▼ 17.22%
+4 hrs · unknown
$3.79 ▼ 15.67%

The stock had already moved +5.39% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ RZLT · stock on Yahoo Finance ↗

See more from November 13, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.